Gapping up
In reaction to earnings/guidance:
- BOH +2.9%, OTIS +1.6%, SMPL +1.6%
M&A news:
- DNKN +17% (issues statement about possible acquistion; confirms that it has held preliminary discussions to be acquired by Inspire Brands)
- SWI +4.7% (announces agreement to acquire SentryOne)
- CCEP +1.3% (Coca-Cola European Partners made a non-binding proposal to acquire Coca-Cola Amatil Limited (CCLAY); reports Q3 update)
Other news:
- GRTX +14.4% (Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer)
- MRTX +6% (reports investigational Adagrasib preliminary data demonstrating tolerability and durable anti-tumor activity)
- GBT +3.4% (presented two abstracts at conference provide greater insight into the safety and efficacy of Oxbryta)
- AMRN +2.4% (reports VASCEPA (icosapent ethyl) was found to significantly reduce cardiovascular events in patients with compromised renal function)
- SYRS +2.3% (reports initial data from Phase 1 clinical trial of SY-5609; demonstrates proof of mechanism and support ongoing development)
- VXX +2.3% (trading higher with futures under pressure)
- EBON +2.1% (files for 5 mln share best-efforts offering and related warrants)
- MRNA +1.2% (announces supply agreement with the ministry of public health to supply qatar with mRNA vaccine against COVID-19)
- AZN +1% (confirms FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial)
Analyst comments:
- PSO +4% (upgraded to Buy from Neutral at UBS)
- RRC +0.9% (upgraded to Buy from Neutral at BofA Securities)
- KTB +0.5% (upgraded to Buy from Underperform at BofA Securities)
- FTI +0.5% (upgraded to Buy from Hold at Societe Generale)